Clinical Trial of the Combination of Trastuzumab (Herceptin) and Tanespimycin in Patients With Solid Tumors and Her2 Positive Metastatic Breast Cancer That Have Previously Failed Herceptin

NCT00773344 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

COMPLETED

Status

25

Enrollment

INDUSTRY

Sponsor class

Conditions

Solid Tumors
Breast Cancer

Interventions

DRUG: Tanespimycin

Sponsor

Bristol-Myers Squibb